The AML1/ETO fusion transcript can be detected by reverse transcription polymerase chain reaction (RT-PCR) in patients with t(8;21)-associated acute myeloid leukemia (AML) in longterm complete remission (CR). Quantitation of the amount of the fusion transcript during CR may therefore be more predictive of cure or relapse than a simple qualitative assessment. Real Time PCR, a fluorometric-based technique, allows simple and rapid quantitation of a target sequence during the extension phase of PCR amplification, in contrast to end-point quantitative methods. Six patients with t(8;21)(q22;q22) AML, who achieved CR were studied by Real Time RT-PCR at different time intervals following diagnosis and high-dose cytarabine and anthracycline-based induction therapy. Five patients had a diagnostic bone marrow (BM) sample available for molecular analysis. Each patient showed у10 3 copies of the AML1/ETO fusion transcript at diagnosis, and each showed a 2-to 4-log decrease in copy number following successful induction chemotherapy. This is comparable to the log-fold reduction in leukemic blasts that is thought to occur in patients successfully cytoreduced into CR by induction chemotherapy. The sixth patient showed a relatively high copy number immediately following successful remission induction chemotherapy, which continued to increase during early CR and was later followed by relapse. Real Time RT-PCR appears to offer advantages over previously used quantitative RT-PCR methods by providing absolute quantitation of the target sequence, expanding the dynamic range of quantitation to over six orders of magnitude, eliminating the post-PCR processing, and reducing labor and carryover contamination. These features make this an attractive method to prospectively evaluate the prognostic value of AML1/ETO fusion transcript quantitation in a larger patient population with t(8;21)(q22;q22) AML in CR.
Introduction
Karyotype is an independent prognostic factor in acute myeloid leukemia (AML). 1 In almost all the studies of adult de novo AML, the presence of t(8;21)(q22;q22) is associated with the highest complete remission (CR) rate (ෂ90%) and the highest probability (50-70%) of remaining in CR at 5 years. At the molecular level, the t(8;21) translocation results in the fusion of the ETO gene, at chromosome band 8q22, with the AML1 gene, at chromosome band 21q22, creating a novel fusion gene AML1/ETO on the derivative chromosome 8. [2] [3] [4] Amplification of AML1/ETO fusion transcript by nested reverse transcription polymerase chain reaction (RT-PCR) has been used to detect minimal residual disease (MRD) in patients with t(8;21)-associated AML in CR. 5 Several studies have reported AML1/ETO fusion transcript detection by nested RT-PCR in patients in long-term CR treated for t(8;21)-associated AML with conventional chemotherapy or autologous bone marrow transplantation (ABMT). [6] [7] [8] Similarly, persistence of the AML1/ETO fusion transcript has also been found in post-remission bone marrow (BM) samples from patients who underwent allogeneic BMT, despite a variety of myeloablative regimens, and acute and/or chronic graft-versus-host disease. 9 These data suggest that the current treatment modalities do not invariably eradicate cells that express AML1/ETO, and that a positive nested RT-PCR for the fusion transcript during CR is not useful to distinguish between patients who are cured and those destined to relapse. It is, therefore, possible that a sensitive quantitative RT-PCR may be a more valuable method for a prognostic assessment of MRD in patients with t(8;21)-associated AML, allowing identification of a critical level of AML1/ETO fusion transcript above or below which relapse or cure can be predicted, respectively. Two recent studies have reported promising results using quantitative competitive RT-PCR (QcRT-PCR) to evaluate the amount of AML1/ETO fusion transcript in remission BM samples from a small number of patients with AML and t(8;21). 10, 11 The technique utilized in these studies, however, has significant disadvantages including intensive labor, a limited dynamic range of quantitation, and the requirement for visual estimates of band intensity following transfer of amplification end products to an ethidium bromidestained gel. Thus, it may not be feasible for validation in a larger patient population.
The development of a fluorometric method for cycle-tocycle quantitation of PCR product growth rate (ie Real Time RT-PCR), promises to provide a more appealing molecular tool for a rapid and accurate quantitation of nucleic acid sequences. [12] [13] [14] In contrast to current end-point RT-PCR-based methodologies, such as QcRT-PCR, Real Time RT-PCR offers several advantages, and may be particularly useful for a large prospective analysis of MRD in leukemia patients.
In the current study we tested the feasibility of the Real Time RT-PCR to detect and quantitate the AML1/ETO fusion transcript in sequential post-remission BM samples from six patients with t(8;21)-associated AML.
Materials and methods
Real Time RT-PCR is based on the use of the 5Ј nuclease activity of Taq polymerase to cleave a nonextendible hybridization probe during the extension phase of the PCR. A targetspecific detection probe, in this case spanning the AML1/ETO fusion cDNA, labeled with a reporter fluorescent dye, FAM (6-carboxyfluorescein), at the 5Ј end and a fluorescence dye quencher, TAMRA (6-carboxy-tetramethyl-rhodamine), at the 3Ј end, hybridizes to the target (ie AML1/ETO cDNA) (Figure 1a) . During the extension phase of the PCR, the nucleolytic activity of the Taq DNA polymerase cleaves the probe from the target, and releases the reporter fluorescent dye from the vicinity of the fluorescence dye quencher. This process results in augmentation of a specific FAM fluorescence signal ( Figure 1b) . The fluorescence signal increases with each amplification cycle and is proportional to the starting amount of the AML1/ETO fusion transcript present in the sample (Figure 1c) . The target-specific signal is detected at a threshold of 10 standard deviations above the baseline fluorescence by a charge-coupled device (CCD) camera, attached to the ABI PRISM 7700 Sequence Detector (Perkin-Elmer Applied Biosystems, Foster City, CA, USA). The CCD camera measures the target-specific signal fluorescent emission spectra from 500 to 650 nm at defined time intervals (ie every 7 s) in real time. An amplification curve is thus constructed comparing PCR cycle number vs ⌬Rn of a given sample (Figure 2 ). The value ⌬Rn, calculated by the 7700 Sequence Detector software (Sequence Detector V 1.6; Perkin-Elmer Applied Biosystems), is defined as the normalized target-specific fluorescence signal (fluorescence signal of the reporter dye divided by the fluorescence signal of the quencher) minus the baseline fluorescent signal established in the first 10 cycles of the PCR. The ⌬Rn increases during the AML1/ETO amplification until the reaction reaches a plateau. From the amplification curve it is possible to determine the parameter C T (threshold cycle), defined as that PCR cycle at which the reporter fluorescence dye, cleaved from the AML1/ETO probe, generates a target-specific detection signal (⌬Rn) that passes the threshold above the baseline. The larger the starting copy number of the AML1/ETO fusion transcript, the sooner the specific signal is detected and the lower is the C T value.
Using a limiting serial dilution of a standard, in this case a cloned AML1/ETO cDNA, a curve plotting the C T vs the known copy number of each standard sample is constructed and used to calculate the AML1/ETO fusion transcript copy number in unknown patient samples.
Patient samples
Six patients (Unique Patient Number (UPN) 1-6) with a diagnosis of AML French-American-British (FAB) M2 and t(8;21)(q22;q22) were studied at different time-points following achievement of CR. All patients provided informed consent and received induction therapy with high-dose cytarabine (HIDAC) plus idarubicin (IDA). 15 Post-induction therapy included either one course of HIDAC/IDA followed by one course of etoposide 3.6 g/m 2 plus cyclophosphamide 50 mg/kg × 4 days (VP16/CY) (UPN 2), or a single intensification treatment with HIDAC/IDA (UPNs 1, 3 and 4), or VP16/CY (UPNs 5 and 6). Response criteria were defined according to the recommendations of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in AML. 16 For five of the six patients, a diagnostic and three to five follow-up BM samples were studied. For the remaining patient (UPN 6) only three post-remission and one
Figure 2
Amplification curves for a set of cloned AML1/ETO cDNA standards. The value ⌬Rn, on the y-axis, is defined as the normalized target-specific fluorescence signal (fluorescence signal of the reporter dye divided by the fluorescence signal of the quencher) minus the baseline fluorescence. It is plotted against the number of PCR cycles, on the x-axis. The amplification curve is shifted to the right as the starting AML1/ETO cDNA copy number is reduced, since fewer copies of the fusion transcript require greater amplification to generate a specific fluorescence signal (⌬Rn) which reaches a detection threshold. The C T (threshold cycle) value, defined as that PCR cycle at which the ⌬Rn passes a threshold of 10 standard deviations above the baseline fluorescence, is thus determined for each sample (arrow). The amplification reaction for each cDNA sample was performed in quadruplicate and the mean ± the standard error C T value was determined for each sample. The SEM was Ͻ1% for each cDNA sample.
relapse BM samples were available. Median follow-up was 20.4 (range 14.3-47.4) months. At the time of this analysis four patients (UPNs 1, 3, 5 and 6) had relapsed. Three (UPNs 1, 3 and 6) of the four were treated in first relapse with a matched sibling allogeneic BMT and one (UPN 5) was treated in first relapse with ABMT. BM samples were also obtained from three normal donors following informed consent and were used as negative controls.
RNA extraction and reverse transcription
Frozen cells from patient BM samples were thawed viably (Ͼ90% by trypan blue exclusion) and placed in RNAzol (Biotecx Laboratories, Houston, TX, USA). Total RNA was extracted following the manufacturer's directions. RNA was quantitated, aliquoted and stored at −70°C until further use. RNA was prepared in a laboratory physically separate from the area where RT was performed. RT was performed with approximately 2.0 g of total RNA, random hexamers (PerkinElmer), and MMLV reverse transcriptase (Gibco, Gaithersburg, MD, USA), following manufacturers' directions.
Production of an AML1/ETO cDNA standard
The AML1/ETO fusion transcript was amplified by single round RT-PCR from the AML1/ETO+ Kasumi 1 cell line, using previously published primers and conditions. 9 The 166 bp amplified product was purified using a Qiagen PCR purification kit (Qiagen, Chatsworth, CA, USA), and then cloned into the p2.1 vector (Invitrogen, San Diego, CA, USA), according to the manufacturers' directions. A plasmid of ෂ4.0 kb was purified using a Qiagen maxi prep kit (Qiagen), according to the manufacturer's directions. The plasmid was quantitated and diluted 10 3 -fold in DNase, RNase-free H 2 O (Sigma, St Louis, MO, USA). A limiting serial dilution was then performed to obtain a set of standards ranging from 4 × 10 7 to four copies of AML1/ETO fusion transcript/l H 2 O.
Construction of the AML1/ETO 'standard curve'
Real Time PCR amplifications of the serially diluted AML1/ETO standard samples were each performed using 2.5 l of cloned AML1/ETO cDNA, 12.5 l of 2 × Master Mix (8% glycerol, 1 × TaqMan buffer A, 200 M dATP, 200 M dCTP, 200 M dGTP, 400 M dUTP, 0.05 U/l AmpErase uracil N-glycosylase, 5 mM MgCl 2 , 0.01 U/l Gold Amplitaq DNA polymerase (Perkin-Elmer), 2.5 l AML1/ETO detection probe at a final concentration of 200 nM and 5 l AML1/ETO forward/reverse primers at a final concentration of 900 nM. The reaction was brought up to a final volume of 25 l adding 2.5 l DNase, RNase-free H 2 O. Sequences of the AML1/ETO detection probe and primers were designed using the Primer Express program (PE Applied Biosystems) and are listed in Table 1 .
PCR reactions were set up in a MicroAmp Optical 96-Well Reaction Plate (Perkin-Elmer). Each well was closed with MicroAmp Optical caps (Perkin-Elmer), following complete loading with reagents as described above. Amplification conditions were 2 min at 50°C and 10 min at 95°C for the first cycle followed by 40 cycles at 95°C for 15 s and 60°C for 1 min. All reactions were performed in the Model 7700 Sequence Detector. Reaction conditions were programmed on a Machintosh 7100 (Apple Computer, Santa Clara, CA, USA) linked directly to the Model 7700 Sequence Detector. Analysis of data was also performed on the Macintosh Computer using the Sequence Detector V 1.6 program. All the reactions for the AML1/ETO standards were run in quadruplicate, and the ⌬Rn and C T were averaged from the values obtained in each reaction. A 'standard curve' was then constructed plotting the C T vs the known copy number of each standard sample.
Quantitation of the AML1/ETO fusion transcript in unknown patient samples
Amplifications of the AML1/ETO fusion transcript for the patients and the negative controls were performed by Real Time PCR using 2.5 l of patient or negative control cDNA, and the conditions described above for the AML1/ETO cDNA standards. All the reactions for the patient and negative control samples were run blinded and in duplicate, and the ⌬Rn and C T were averaged from the values obtained in each reaction. Calculation of the absolute AML1/ETO fusion transcript 
Normalization of patient samples to a housekeeping gene
In order to minimize variability in the results due to differences in the RT efficiency and/or RNA integrity among the unknown patient samples, the absolute AML1/ETO fusion transcript copy number was normalized to an internal housekeeping gene, ie ␤-actin.
A semilogarithmic limiting dilution of commercially available human genomic DNA (Perkin-Elmer), ranging from 9.3 × 10 2 to 1.9 × 10 4 copies/l, was used to construct a ␤-actin standard curve. Real Time PCR amplification of the human genomic DNA standards were each performed using 2.5 l of DNA, 2.5 l ␤-actin detection probe, 5 l ␤-actin forward/reverse primers and the conditions described above for the AML1/ETO fusion transcript amplification. The ␤-actin detection probe and primers were obtained from Perkin-Elmer and are listed in Table 1 .
Amplification of the ␤-actin transcript for the patients and negative controls was performed using 2.5 l of patient or negative control cDNA, 2.5 l ␤-actin detection probe, 5 l ␤-actin forward/reverse primers and the conditions described above for the AML1/ETO transcript amplification. ␤-actin transcript copy number was thus calculated for each patient and negative control, using the ␤-actin standard curve. The normalized values of the AML1/ETO fusion transcript copies in each patient and control sample were reported as the ratio of AML1/ETO fusion transcript copy number/␤-actin transcript copy number × 1000. The normalized AML1/ETO fusion transcript copy number was р0.13 in three BM samples obtained from normal donors. Twenty-four of the 29 patient samples were analyzed by Real Time RT-PCR in a single batch. Four additional samples were analyzed in a second batch. A single set of AML1/ETO and ␤-actin standard curves was utilized for quantitation of all samples.
The results obtained normalizing the AML1/ETO fusion transcript to ␤-actin were also confirmed using an alternate housekeeping gene, ie GAPDH. The mRNA GAPDH sequence amplified was a 226 bp amplicon, starting at base 1457 of the genomic sequence (HUMGAPDH, J04038, in GenBank), spanning two introns (intron number 2 from base 1482-3116 and intron number 3 from base 3216-3306), and ending at base 3412. A GAPDH standard curve was constructed utilizing a limiting dilution of cDNA synthesized from commercially available human RNA (Perkin-Elmer). GAPDH transcript in the unknown patient samples was amplified and quantitated under the same PCR conditions described for the AML1/ETO and ␤-actin transcripts. Figure 1 and is detailed in Materials and methods. Using a limiting dilution of a known quantity of an AML1/ETO cDNA standard, ranging from 4 to 4 × 10 7 AML1/ETO copies/l, it was possible to obtain a series of amplification plots and determine their relative C T values (Figure 2) . A curve was then constructed plotting the C T vs the known copy number of each standard sample (Figure 3) . Since the C T value decreased lin- early with the increasing amount of AML1/ETO copy number present in each standard sample, quantitation of the AML1/ETO fusion transcript in an unknown patient sample could be accomplished by measuring the C T and using the standard curve to calculate the absolute AML1/ETO fusion transcript copy number in a range of eight orders of magnitude. The absolute AML1/ETO fusion transcript copy number was then normalized to an endogenous control, ie ␤-actin transcript, and the results were confirmed using an alternate housekeeping gene transcript, ie GAPDH (data not shown). 13 A total of 29 BM samples from six patients with AML FAB M2 and t(8;21)(q22;q22) were analyzed using the Real Time RT-PCR. For five of the six patients, diagnostic and three to five post-remission BM samples were studied ( Table 2 ). All the reactions for the patient and negative control samples were run blinded and in duplicate, and the ⌬Rn and C T were averaged from the values obtained in each reaction with a standard error of the mean Ͻ1% for each sample. It was noted that the AML1/ETO fusion transcript copy number ranged between 1119.9 and 8999.4 per 1000 copies of ␤-actin in the five diag-
Results

A schematic illustration of the Real Time PCR is shown in
Figure 3
The AML1/ETO cDNA standard curve. The C T decreases linearly with increasing copy numbers of the AML1/ETO cDNA. The standard curve can then be used to calculate the absolute AML1/ETO fusion transcript copy number present in an unknown patient sample, following reverse transcription and determination of the relative C T value during the Real Time PCR amplification.
nostic BM samples. The percent leukemic blasts in these diagnostic samples were 25% (UPN 1), 31% (UPN 2), 75% (UPN 3), 90% (UPN 4) and 86% (UPN 5). A direct correlation between percent blasts and AML1/ETO fusion transcript copy number per 1000 copies of ␤-actin could not be established. However, all diagnostic samples had у10 3 copies of the AML1/ETO fusion transcript per 1000 copies of ␤-actin (Figure 4) .
In two of three relapse samples available for molecular analysis, the numbers of AML1/ETO fusion transcript copies were Ͼ10 3 , ie 1772.8 (UPN 5) and 1869.3 (UPN 6) per 1000 copies of ␤-actin, similar to that found at diagnosis in all five patients. There were greater than 50% blasts in both relapse samples. In the third relapse sample (UPN 1), there were 8.6% blasts detected and the t(8;21)(q22;q22) was detected on cytogenetic analysis. Despite this, there were only 10.3 AML1/ETO fusion transcript copies present per 1000 copies of ␤-actin in the same sample (Figure 4 ). There was between 10-and 100-fold difference in AML1/ETO expression when comparing the diagnostic and relapse samples in this patient, even when corrected for the difference in the percent of blasts. The results were verified using a second housekeeping gene, ie GAPDH. A fourth patient who relapsed (UPN 3) did not have material available for molecular analysis.
All five patients for whom diagnostic material was available demonstrated a 2 to 4 log-fold reduction in AML1/ETO fusion transcript copy number following achievement of CR with dose-intensive induction chemotherapy. The first post-induction sample examined from each of these five patients expressed Ͻ10
2 copies of AML1/ETO fusion transcript per 1000 copies of ␤-actin. Thereafter, samples from all six patients in pathologic and cytogenetic CR demonstrated AML1/ETO fusion transcript copies that varied between 0.03 and 347.7 per 1000 copies of the ␤-actin transcript (Figure 4 ).
For UPN 6, a diagnostic sample was not available for quantitation of the AML1/ETO fusion transcript. However, in contrast to the other five patients who all expressed Ͻ10 2 copies of the AML1/ETO fusion transcript per 1000 copies of ␤-actin, the first post-induction sample examined for UPN 6 expressed 121.8 copies of AML1/ETO fusion transcript per 1000 copies of ␤-actin. If one assumes that a diagnostic sample from UPN 6 was likely to have between 10 3 and 10 4 copies of AML1/ETO fusion transcript like the other five cases, then UPN 6 did not undergo a similar reduction in copy number immediately following successful induction chemotherapy, as seen in the other patients. A steady increase in AML1/ETO fusion transcript copy number thereafter during the first 7 months of continuous CR preceded a clinical relapse 32 months after diagnosis (Figure 4) .
Discussion
In the current study we tested the feasibility of Real Time RT-PCR to detect and quantitate AML1/ETO fusion transcript in diagnosis, remission and relapse BM samples from six patients with t(8;21)-associated AML. The hypothesis to ultimately be tested using this technique is that quantitation of AML1/ETO fusion transcript in patients with t(8;21)-associated AML in CR can lead to identification of a critical level of fusion transcript expression that will prove useful in predicting relapse or cure.
Two recent reports have demonstrated the potential prognostic value of AML1/ETO fusion transcript quantitation in a small number of patients using a QcRT-PCR assay. 10, 11 This method employs a known amount of a competitor cDNA, slightly different in size from the AML1/ETO target cDNA but with a presumed equivalent efficiency of target amplification. 17 The competitive cDNA is serially diluted into approximately six tubes, each containing an equivalent but unknown amount of AML1/ETO cDNA from a single patient sample. The equivalence point of the target-to-competitor product ratio at the end of the PCR is used to calculate the starting amount of AML1/ETO cDNA in the unknown patient sample. The dynamic range of quantitation obtained with QcRT-PCR is 2 logs. The best accuracy in estimating the amount of AML1/ETO cDNA in the unknown sample is given by a targetto-competitor ratio of 1:1, visualized after loading the six products on an ethidium bromide-stained gel. The limitations of this procedure are the restricted dynamic range of quantitation and the requirement for visual estimates of equivalence between amplification end products. This technique is, also, very labor intensive, due to the need to perform approximately six amplifications and a gel electrophoresis for each unknown sample. For example, in order to quantitate a cytokine transcript in 29 sequential samples from patients receiving an immune therapy, approximately 600 Qc-RT PCRs had to be performed in our laboratory, with an estimated 300 person hours required for completion of quantitation. 18 Duplicate assays for each sample require nearly twice as much labor as performing a single assay. The labor involved in QcRT-PCR may limit its application for studies of large patient populations.
The use of Real Time RT-PCR, as described in the current study, demonstrates the feasibility of this technique to quantitate the AML1/ETO fusion transcript in BM samples and suggests several advantages over endpoint quantitative RT-PCR methods, such as that described above. First, Real Time RT-PCR quantitation is performed in a closed-tube system and requires no-post-PCR manipulation. Therefore, the potential for carryover contamination is reduced. Second, the use of a 96-well plate system and the automated technology allow rapid and simultaneous quantitation of multiple sequential samples. Third, the time and work necessary for the preparation of the samples and for the preliminary testing of experimental conditions is also greatly reduced. In order to complete quantitation of 29 samples no more than 40 person hours were employed. Duplicate assay for an individual sample can be performed with essentially no additional labor over that required for a single assay. Fourth, the AML1/ETO cDNA standard curve can be quantitated in a range of over six orders of magnitude with a standard error of the mean Ͻ1% for each sample. This results in an expanded dynamic range of absolute quantitation for the AML1/ETO fusion transcript in unknown patient samples. Finally, Real Time RT-PCR also uses quantitation of a housekeeping gene (eg ␤-actin) product to normalize the absolute amount of target cDNA in unknown samples for differences in RNA quality and RT efficiency. We obtained comparable results with the same experimental samples when an alternate housekeeping gene transcript, ie GAPDH was amplified using specific primers which adequately discriminate between DNA and RNA amplification.
The current study was not designed to demonstrate the clinical significance of AML1/ETO fusion transcript detection during CR, but rather to explore the potential use of Real Time RT-PCR for quantitation of MRD to ultimately predict cure or relapse in patients with t(8;21)-associated AML. The small number of samples analyzed and the variable time intervals between quantitations did not allow identification of specific patterns or conditions predictive of cure or relapse. However, several interesting points emerged from the analysis of our results.
First, all the diagnostic and relapse samples, except UPN 1's relapse sample, showed a normalized level of the AML1/ETO fusion transcript of у10 3 copies, suggesting the possibility of a critical threshold above which clinical and morphological disease detection is likely. In the case of UPN 1, a BM sample analyzed in early relapse showed 10.3 AML1/ETO fusion transcript copies similar to that present in the remission samples, despite detection of 8.6% blasts by conventional morphologic analysis and t(8;21) by cytogenetics. Although the possibility of a technical error in the quantitation of the fusion transcript cannot be excluded, this finding would suggest that in a fraction of cases quantitation of AML1/ETO fusion transcript during CR may not reflect the actual amount of MRD or the malignant potential of the chemo-resistant, residual clonal population.
Second, in the five patients for whom diagnostic material was available, a 2-4 log-fold reduction in the amount of fusion transcript was noted during early CR. This decrease of the AML1/ETO fusion transcript is comparable to the 2-3 logfold reduction in leukemic blast cell number that is thought to occur when patients are cytoreduced into CR with standard induction chemotherapy. 19 Similar results have been reported by Tobal and Yin 11 using QcRT-PCR. They found a 2-3 logfold reduction of the AML1/ETO fusion transcript between diagnosis and induction chemotherapy, and a further reduction of approximately 1 log after consolidation chemotherapy. Conversely, as illustrated in UPN 6, a relatively high AML1/ETO fusion transcript copy number (ie у10
2 ) soon after achievement of CR may be indicative of clinically significant residual disease and may ultimately lead to early identification of a group of patients likely to relapse. These data suggest that quantitation of AML1/ETO gene expression may be useful for assessing the initial response to treatment. Furthermore, quantitation of fusion transcript copy number by Real Time PCR at relapse may prove useful in the evaluation of salvage regimens or single experimental agents that are being evaluated for clinical efficacy. A reduction in tumor burden comparable to that seen with successful remission induction at diagnosis might lead to additional consideration of a combination or individual agents, despite failure to achieve a durable second CR.
As noted above, a relatively high and increasing (у10 2 ) AML1/ETO fusion transcript copy number following CR may be predictive of relapse in some patients (eg UPN 6). However, other patients (eg UPNs 4 and 5) at 17.2 and 31.4 months following first and second CR, respectively, have у10 2 AML1/ETO fusion transcript copy numbers, ie 109.1 (UPN 4) and 207.4 (UPN 5), but remain in cytogenetic and clinical CR. It is currently unknown whether the apparent different clinical outcome in these two groups of patients is related to a different lead time to relapse or, indeed, reflects the presence of residual leukemic blasts with similar production of fusion transcript but distinct potentials for the expression of the malignant phenotype. Real Time PCR could be most useful in these situations to detect any significant increase in the fusion transcript copy number toward a critical threshold (ie у10 3 copy number) predictive of impending relapse. The optimal time interval between quantitations during CR and the lead time between detection of a predictive amount of MRD and clinical relapse remain, however, to be determined.
Finally, our findings suggest that there is variation in the level of AML1/ETO fusion transcript expression among patients' blasts. Therefore, the use of a cell line expressing AML1/ETO as a standard to equate the copy number of fusion transcript to the number of blasts may not provide an accurate assessment of the leukemic cell population present in a given sample. We believe that a standard curve using a synthesized AML1/ETO cDNA may be meaningfully applied to all patient samples and provide a useful method to compare specimens from different patients.
In conclusion, these data, although preliminary, confirm the feasibility of Real Time RT-PCR to rapidly and accurately detect and quantitate AML1/ETO fusion transcript in t(8;21)-associated AML. Our study suggests that Real Time PCR is potentially useful to assess early response to treatment and, perhaps, to predict by pattern analysis, ultimate clinical outcome. However, even following the quantitative assessment of AML1/ETO fusion transcript in only three patients with t(8;21)-associated AML who relapsed after intensive chemotherapy, our findings suggest that such analysis will not be straightforward, and ultimately, it may not be possible to assign broad criteria to predict relapse or cure using quantitative RT-PCR. Large prospective studies of patients with t(8;21)-associated AML undergoing uniform treatment and analyzed by Real Time PCR at identical time intervals will be needed to validate our results and determine the prognostic value of MRD quantitation.
